RESUMEN
The study aims to assess groundwater resources in Sinai's central area using remote sensing, geoelectric, and well-logging data, utilising techniques for modelling hydrogeological frameworks and evaluating desert regions' groundwater potential. Its utilized satellite image sources, soil maps, and geological maps to map the effects of various factors on groundwater potentiality recharge, dividing it into five zones. Eighteen deep VES stations were used to examine the upper part of the groundwater aquifer in Central Sinai, Egypt, comparing it with available borehole information (Well-1, and JICA-1) to establish subsurface geology and hydro-geology positioning. Borehole data, VES interpretation results, hydro-geophysical maps, and four geoelectrical cross-sections were used to visualize the rearward expansion of eight lithological units, groundwater-bearing sections, and aquifer-filled thicknesses. From interpretation data output reveal three zones with significant recharge and storage potential, including two groundwater aquifers. The shallow aquifer has a saturation thickness of the fractured limestone of 35-250 m, while the deep aquifer Nubian sandstone is detected at depths ranging from 660-1030 m. NW-SE and NE-SW faults likely recharge conduits connecting shallow and deep aquifers, providing sites with acceptable groundwater potential for living, agriculture, and development in Sinai.
RESUMEN
Application of the herbicide glyphosate in crops is a common practice among farmers around the world. Tomato is one of the crops that are treated with glyphosate to fight weed growth and loss of crop. However, tomato plants often show phytotoxic effects from glyphosate. In this study, the ability of pongamia oil derived from Pongamia pinnata (known also as Millettia pinnata) tree to alleviate the herbicide glyphosate toxicity effects in tomato (S.lycopersicum L. cv. Micro-tom) plants was tested. Tomato plants were treated with a mixture of a dose of (GLY) glyphosate (10 mg kg−1) and different doses of pongamia oil (PO) foliar spray (5, 10, 50, and 100 mM) and compared with the herbicide or oil control (glyphosate 10 mg kg−1 or pongamia oil PO 50 mM). Some morphological features, non-enzymatic and enzymatic antioxidants, and gene expression were observed. Glyphosate-treated plants sprayed with PO 50 mM (GLY + PO 50) showed increased root biomass (0.28 g-p ≤ 0.001), shoot biomass (1.2 g-p ≤ 0.01), H2O2 (68 nmol/g), and the activities of superoxide dismutase (SOD; 40 mg-p ≤ 0.001), catalase (CAT; 81.21 mg-p ≤ 0.05), ascorbate peroxidase (APX; 80 mg-p ≤ 0.01) and glutathione reductase (GR; 53 min/mg-F4,20 = 15.88, p ≤ 0.05). In contrast, these plants showed reduced contents of Malondialdehyde (MDA; 30 nmol/g-F4,20 = 18.55, p ≤ 0.01), O2 (0.6 Abs/g), Prolne (Pro; 345 µg/g), Glutathine (GSH; 341 nmol/mg-p ≤ 0.001), ascorbate (AsA; 1.8 µmol/gm), ascorbic acid (AA; 1.62 mg-p ≤ 0.05) and dehydroascorbate (DHAR; 0.32 mg p ≤ 0.05). The gene expression analysis was conducted for seven oxidative stress related genes besides the house-keeping gene Actin as a reference. The gene CYP1A1450 showed the highest mRNA expression level (6.8 fold ± 0.4) in GLY-treated tomato plants, whereas GLY-treated plants + PO 50 showed 2.9 fold. The study concluded that foliar spray of 50 mM pongamia oil alleviated the toxic effects of glyphosate on tomato plants in the form of increased root and shoot biomass, SOD, CAT, APX, and GR activity, while reduced MDA, O2, Pro, GSH, AsA, AA, DHAR, and gene CYP1A1450 expression.
RESUMEN
BACKGROUND: Standard diagnostic and monitoring methods for glycemic status involve invasive sample collection through venous puncture or fingerstick. Recent attention has been focused on exploring noninvasive methods through oral biofluids. Specifically, serum fructosamine has been established as a short-term (2- to 3-wk) marker of disease status in patients with diabetes. Fructosamine measured through noninvasive means such as saliva has shown promise, but its clinical applicability is unknown. OBJECTIVE: Evaluate the available evidence on using salivary fructosamine as a reliable noninvasive marker to screen and diagnose patients with diabetes mellitus in the clinical setting. A comparative analysis of the correlative accuracy of salivary fructosamine measurements with established blood glycemic biomarkers such as serum fructosamine, blood glucose, and HbA1c will be conducted. METHODS: Six electronic databases (PubMed, PubMed Central, MEDLINE, EMBASE, Scopus, Cochrane Library) were searched for original research papers (clinical and animal studies) that were relevant to the objective of this systematic review. The search was initiated on May 28, 2020. The systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Bias risk assessment, overall quality, and level of evidence were based on the Oxford Centre for Evidence-Based Medicine, Appraisal Tool for Cross-Sectional Studies, and Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies tool. Heterogeneity was assessed using the National Institutes of Health quality assessment tool for cross-sectional studies. RESULTS: A total of 174 records were identified. Full-text articles screened for eligibility (n = 21) identified only 6 original research articles relevant to the research question and were thus included in the systematic review. The types of studies identified were cross-sectional and in vivo studies. Three studies (3/6) showed positive correlation of salivary fructosamine with blood glucose levels, while 1 study (1/6) demonstrated a positive correlation with glycated hemoglobin (HbA1c). Limitations related to sample size and selection were identified along with a fair level of interstudy heterogeneity. CONCLUSION: Based on the evidence evaluated, the utility of salivary fructosamine as a noninvasive marker to screen and diagnose patients with diabetes is doubtful. The overall level of evidence was low (IIIB) and the risk of bias was determined to be high. KNOWLEDGE TRANSFER STATEMENT: Further evidence in the form of large-scale well-controlled studies is needed prior to recommending salivary fructosamine as a noninvasive diagnostic tool for glycemic status in patients with diabetes mellitus.
Asunto(s)
Glucemia , Biomarcadores , Estudios Transversales , Fructosamina , Hemoglobina Glucada/análisis , Humanos , Estados UnidosRESUMEN
BACKGROUND AND PURPOSE: Endovascular therapy has become the standard of care for patients with disabling anterior circulation ischemic stroke due to proximal intracranial thrombi. Our aim was to determine whether the beneficial effect of endovascular treatment on functional outcome could be explained by a reduction in posttreatment infarct volume in the Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT) trial. MATERIALS AND METHODS: The REVASCAT trial was a multicenter randomized open-label trial with blinded outcome evaluation. Among 206 enrolled subjects (endovascular treatment, n = 103; control, n = 103), posttreatment infarct volume was measured in 204 subjects. Posttreatment infarct volumes were compared with treatment assignment and recanalization status. Appropriate statistical models were used to assess the relationship among baseline clinical and imaging variables, posttreatment infarct volume, the 24-hour NIHSS score, and functional status with the 90-day modified Rankin Scale score. RESULTS: The median posttreatment infarct volume in all subjects was 23.7 mL (interquartile range = 68.9 mL) and 16.3 mL (interquartile range = 50.2 mL) in the endovascular treatment arm and 38.6 mL (interquartile range = 74.9 mL) in the control arm (P = .02 for endovascular treatment versus control subjects). Baseline NIHSS (P < .01), site of occlusion (P < .03), baseline NCCT ASPECTS (P < .01), and recanalization status (P = .02) were independently associated with posttreatment infarct volume. Baseline NIHSS (P < .01), time from symptom onset to randomization (P = .02), treatment type (P = .04), and recanalization status (P < .01) were independently associated with the 24-hour NIHSS scores. The 24-hour NIHSS score strongly mediated the relationship between treatment type and 90-day mRS (P < .01 for indirect effect when adjusted for age), while posttreatment infarct volume did not (P = .26). CONCLUSIONS: Endovascular treatment saves brain and improves 90-day clinical outcomes primarily through a beneficial effect on the 24-hour stroke severity.
Asunto(s)
Revascularización Cerebral/métodos , Accidente Cerebrovascular/patología , Accidente Cerebrovascular/terapia , Anciano , Anciano de 80 o más Años , Procedimientos Endovasculares/métodos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
CONTEXT: Postmenopausal osteoporosis is mostly caused by increased bone remodeling resulting from estrogen deficiency. Hormone replacement therapy (HRT) is used to prevent osteoporosis, but it increases the risk for breast cancer, thromboembolism, strokes, and heart attacks. Pomegranate seed oil extract (SOE) is rich in phytoestrogen and antioxidant compounds. OBJECTIVES: To evaluate the therapeutic role of SOE against bone turnover, resorption and osteoporosis induced in ovariectomized rats as a postmenopausal model and comparing the results with those from Generic CycloProgynova drug (D). DESIGN: The study used western albino rats undergo bilaterally ovariectomization as a model for postmenopausal. SETTING: The study took part in a laboratory setting. ANIMALS: Forty female western albino rats (age: 3-4 months) weighing 150-180 gm. MEASUREMENTS: Rats were divided into four groups, 10 rats each; SC-group: Sham control = untreated and unovariectomized rats; OVX-group = ovariectomized rats; (OVX-SOE) and (OVX-D) groups = OVX rats were treated with SOE and D, respectively. Bone markers (BMs) especially osteocalcin (BGP), alkaline phosphatase (ALP), tartarate resistance acid phosphatase (TRAcP), bone weight, bone calcium concentration, serum electrolytes (calcium, sodium and potassium) and serum estradiol (E2) level and histopathological examination of bones were determined. Also lipid profile, uric acid, prothrombin time (INR) and liver and kidney functions were measured to evaluate the adverse effects of SOE and D. RESULTS: In OVX group the activities of ALP and TRAcP and the levels of BGP, serum calcium, sodium and body weight were significantly higher (p≤0.05) than SC-group, while bone calcium concentration, bone mass, serum E2 and potassium level as well as uterus mass were significantly lower (p≤0.05). Also histopathological results revealed that the outer cortical bone became thinner, while the cancellous bone trabeculae lost their normal architecture. Moreover in OVX group lipid profile and uric acid levels were significantly higher (p≤0.05) than SC group, but there were no significant changes (p≤0.05) in INR level, liver and kidney functions. Treatment of OVX rats with SOE or D for 12 weeks improved both the architecture of bones as shown from the histopathological results and BMs, serum electrolytes and E2 levels (p≤0.05) which approached SC-group. Moreover after treatment of OVX rats with SOE the levels of lipid profile and uric acid were improved and approached SC-group, while liver function became significant lower (p≤0.05) than SC-group. Also there were no significant changes (p≤0.05) in kidney functions and INR of (OVX-SOE), OVX and SC groups. In contrast in (OVX-D) group the levels of lipid profile, liver and kidney functions, uric acid and INR were significantly higher (p≤0.05) than those of OVX and SC groups. CONCLUSION: The results of this study show that SOE has therapeutic effects on osteoporosis, while it has no adverse effects on lipid profile, uric acid, liver and kidney functions when compared to HRT. SOE offers a promising alternative in the design of new strategies in nutritional management of age-related bone complications.
Asunto(s)
Remodelación Ósea/efectos de los fármacos , Resorción Ósea/tratamiento farmacológico , Huesos/efectos de los fármacos , Lythraceae/química , Extractos Vegetales/farmacología , Aceites de Plantas/farmacología , Semillas/química , Albinismo , Animales , Biomarcadores/análisis , Peso Corporal/efectos de los fármacos , Huesos/metabolismo , Huesos/patología , Modelos Animales de Enfermedad , Femenino , Humanos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Osteoporosis Posmenopáusica/prevención & control , Ovariectomía , Extractos Vegetales/química , Aceites de Plantas/química , Ratas , Ratas Sprague-DawleyRESUMEN
OBJECTIVES: Few studies have compared oral mucous membrane pemphigoid (MMP) and pemphigus vulgaris (PV). Descriptive analysis of oral features, extent of extra-oral involvement, and management outcomes were performed. SUBJECTS AND METHODS: Patients with PV and MMP, the latter with exclusive oral involvement at first presentation, were included. RESULTS: There were 26 MMP (46%) and 31 PV (54%) patients. Desquamative gingivitis was evident in 84% of MMP cases compared to 28% of PV cases (P < 0.05). Non-gingival lesions were noted in 6% of MMP cases compared to 55% of PV cases (P < 0.01). Management of MMP consisted of only topical corticosteroids in 88% of cases while 12% of cases required concomitant systemic therapy. All PV cases (100%) required systemic therapy. No patients with MMP developed scarring or ocular lesions, and one patient (4%) developed cutaneous lesions. Five PV cases (16%) had oral cavity involvement only with three (60%) developing pharyngeal involvement and two (40%) developing cutaneous lesions on follow-up. CONCLUSION: Oral MMP presents primarily as desquamative gingivitis, infrequently involving extragingival sites, and is highly amenable to topical therapy, while PV is a systemic mucocutaneous disease with extensive non-gingival oral lesions that almost always requires systemic therapy.
Asunto(s)
Enfermedades de la Boca/diagnóstico , Penfigoide Benigno de la Membrana Mucosa/diagnóstico , Pénfigo/diagnóstico , Administración Oral , Administración Tópica , Corticoesteroides/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios/uso terapéutico , Diagnóstico Diferencial , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Enfermedades de la Boca/tratamiento farmacológico , Enfermedades de la Boca/patología , Mucosa Bucal/patología , Penfigoide Benigno de la Membrana Mucosa/tratamiento farmacológico , Penfigoide Benigno de la Membrana Mucosa/patología , Pénfigo/tratamiento farmacológico , Pénfigo/patología , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Novel benzimidazoles, benzothiazoles and benzofurans incorporating pyrazole moiety have been synthesized and screened for their antiangogenic activities, by testing their ability to inhibit human umbilical vein endothelial cell (HUVEC) proliferation, cord formation and migration in response to chemoattractant. 3 compounds 19, 23 and 26 showed antiangiogenic activities at non-cytotoxic concentrations. Compound 19 was the most active with chemotaxis activity data nearly comparable to that of the positive control, TNP-470. Compound 42 showed a significant cytotoxic effect on the tested cancer cell lines and less antiangiogenesis activity compared to compounds 19, 23 and 26. All the tested compounds, in contrary to TNP-470, interfered with the migratory function of HUVECs in response to vascular endothelial growth factor rather than the endothelial cells proliferation or cord formation. Moreover, a docked pose of compounds 19 and 26 was obtained bound to kinase insert domain receptor using Molecular Operating Environment module.
Asunto(s)
Inhibidores de la Angiogénesis/síntesis química , Inhibidores de la Angiogénesis/farmacología , Bencimidazoles/síntesis química , Bencimidazoles/farmacología , Benzofuranos/síntesis química , Benzofuranos/farmacología , Benzotiazoles/síntesis química , Benzotiazoles/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Diseño de Fármacos , Ensayos de Selección de Medicamentos Antitumorales , Células Endoteliales/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana , Humanos , Indicadores y Reactivos , Espectroscopía de Resonancia Magnética , Pirazoles , Espectrofotometría Infrarroja , Relación Estructura-ActividadRESUMEN
Experimental testing of growth, metastatic progression and drug responsiveness of human breast cancer in vivo is performed in immunodeficient mice. Drug candidates need to show promise against human breast cancer in mice before being allowed into clinical trials. Breast cancer growth is under endocrine control by ovarian steroids and the pituitary peptide hormone prolactin. While it is recognized that the most relevant biologic effects of prolactin are achieved with prolactin from the matching species, the biologic efficacy of mouse prolactin for human prolactin receptors has not been recorded. Thus, it is unclear whether the mouse endocrine environment adequately reflects the hormonal environment in breast cancer patients with regard to prolactin. We now show both recombinant and natural pituitary-derived mouse prolactin to be a poor agonist for human prolactin receptors. Mouse prolactin failed to induce human prolactin receptor-mediated biologic responses of cell clustering, proliferation, gene induction and signal transduction, including activation of Stat5, Stat3, Erk1/2 and Akt pathways. Consistent data were derived from human breast cancer lines T-47D, MCF-7 and ZR-75.1, as well as human prolactin receptor-transfected COS-7 and 32D cells. Failure of mouse prolactin to activate human prolactin receptors uncovers a key deficiency of the mouse endocrine environment for human xenotransplant studies. Since most human breast cancers express prolactin receptors, human breast cancer transferred into mice is unnaturally selected for growth in the absence of circulating prolactin. The new insight raises concerns about the validity of analyzing biology and drug responsiveness of human breast cancer in existing mouse xenotransplant models.
Asunto(s)
Neoplasias de la Mama/metabolismo , Prolactina/farmacología , Receptores de Prolactina/metabolismo , Análisis de Varianza , Animales , Neoplasias de la Mama/patología , Línea Celular Tumoral , Proliferación Celular , Electroporación , Femenino , Humanos , Immunoblotting/métodos , Inmunoprecipitación/métodos , Ratones , Ratones Desnudos , Modelos Animales , Trasplante de Neoplasias , Prolactina/metabolismo , Unión Proteica , Receptores de Prolactina/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Transcripción STAT5/metabolismo , Especificidad de la Especie , Trasplante HeterólogoRESUMEN
N-Acetylglucosaminyltransferase III (GnT-III) produces "bisecting-GlcNAc" and regulates the branching of N-glycans. GnT-III activity is elevated during hepatocarcinogenesis, which is in contrast to the undetectable level found in normal hepatocytes. To determine the biological significance of GnT-III in hepatocytes, transgenic mice that specifically express GnT-III in the liver were established and characterized. The transgenic hepatocytes had a swollen oval-like morphology, with many lipid droplets. Apolipoprotein B, which contained increased level of bisecting-GlcNAc accumulated in the transgenic hepatocytes. In the transgenic serum, triglycerides, the beta- and pre-beta-lipoprotein fractions, and apolipoprotein B100 were significantly decreased, compared with levels in nontransgenic serum. These abnormal phenotypes were more prominent in the mice with more copies of the transgene and a resulting high GnT-III activity. We demonstrate that aberrant glycosylation, as the direct result of the formation of bisecting-GlcNAc, disrupts the function of apolipoprotein B, leading to the generation of fatty liver. This observation suggests a novel mechanism for the pathogenesis of fatty liver.
Asunto(s)
Apolipoproteínas B/biosíntesis , Hígado/enzimología , Hígado/patología , N-Acetilglucosaminiltransferasas/biosíntesis , Animales , Apolipoproteínas B/sangre , Conformación de Carbohidratos , Secuencia de Carbohidratos , Glicosilación , Lipoproteínas LDL/sangre , Lipoproteínas VLDL/sangre , Hígado/citología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos DBA , Ratones Transgénicos , Datos de Secuencia Molecular , N-Acetilglucosaminiltransferasas/genética , N-Acetilglucosaminiltransferasas/metabolismo , Oligosacáridos/biosíntesis , Oligosacáridos/química , Polisacáridos/biosíntesis , Polisacáridos/química , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/metabolismo , Componente Amiloide P Sérico/biosíntesis , Triglicéridos/sangreRESUMEN
The bisecting N-acetylglucosamine residue is formed by UDP-N-acetylglucosamine:beta-D-mannoside-beta-1, 4-N-acetylglucosaminyltransferase III (GnT-III), a key branching enzyme for N-glycans. We found that forskolin, an adenylyl cyclase activator, markedly enhanced GnT-III at the transcriptional level in various hepatoma cells and hepatocytes, resulting in an increase of bisecting GlcNAc residues in various glycoproteins, as judged from the lectin binding to erythroagglutinating phytohemagglutinin (E-PHA). In whole cell lysates, the E-PHA binding was increased, and leukoagglutinating phytohemagglutinin (L-PHA) binding was decreased at 12 h after forskolin treatment, by time, both GnT-III activity and mRNA had reached the maximum levels. In contrast, the binding capacity as to E-PHA, determined by fluorescence-activated cell sorting on the cell surface, was decreased, suggesting that bisecting GlcNAc structures in certain glycoproteins changed the expression levels of glycoproteins and decreased their sorting on the cell surface. Fractionated organelles of M31 cells showed that the binding capacity as to E-PHA was mainly localized in Golgi membranes and lysosomes. This was also supported by a fluorescence microscopy. In order to determine whether or not the bisecting GlcNAc residue acts as a sorting signal for glycoproteins, N-oligosaccharide structures of lysosomal-associated membrane glycoprotein 1 and beta-glucuronidase, gamma-glutamyltranspeptidase, and secretory glycoproteins such as ceruloplasmin and alpha-fetoprotein were measured by E-PHA and L-PHA blotting after immunoprecipitation. The expression levels of lysosomal membrane glycoprotein 1 and gamma-glutamyltranspeptidase on the cell surface were decreased at 12 h after forskolin treatment, indicating that the bisecting GlcNAc structure may act as a negative sorting signal for the cell surface glycoproteins and may alter the characteristics of hepatoma cells. This is the first report on glycoprotein sorting related to a specific structure of oligosaccharides, bisecting GlcNAc.
Asunto(s)
Acetilglucosamina , Colforsina/farmacología , Neoplasias Hepáticas Experimentales/metabolismo , Glicoproteínas de Membrana/química , Glicoproteínas de Membrana/metabolismo , N-Acetilglucosaminiltransferasas/metabolismo , Oligosacáridos/química , Animales , Conformación de Carbohidratos , Secuencia de Carbohidratos , Línea Celular , Citometría de Flujo , Expresión Génica , Hígado/enzimología , Ratones , Datos de Secuencia Molecular , N-Acetilglucosaminiltransferasas/biosíntesis , Oligosacáridos/metabolismo , Fitohemaglutininas , Ratas , Células Tumorales CultivadasRESUMEN
The present study compares self-rated depressive symptoms of 95 inpatients with depressive syndromes: 45 in Germany and 50 in Egypt. In each country, 50 patients suffering from acute internal diseases served as controls. Psychiatric patients were selected according to DSM-III criteria for major depressive disorder (MDD). Depressive symptoms and depth of depression were scored by the Beck Depression Inventory (BDI). The self-rating of depressive symptoms proved sufficient for transcultural comparison, provided controls are used, and was more practicable than observer rating scales. The results indicate higher BDI total scores for Egyptian than for German inpatients. This appear to be due to cultural differences, presumably mostly in language performance ("tendency to hyperbole"). Moreover, Egyptians complained more about somatic symptoms, as has already been frequently suggested on the basis of clinical observations.
Asunto(s)
Comparación Transcultural , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/psicología , Hospitalización , Adulto , Factores de Edad , Trastorno Depresivo/etnología , Egipto , Femenino , Alemania , Humanos , Masculino , Psicometría , Factores Sexuales , Factores SocioeconómicosRESUMEN
On the background of social-cognitive theories and transcultural aspects of depression relationships between generalized locus of control orientations and indicators of depression were analyzed in clinical samples from Egypt and West Germany. Data were collected in samples of 50 Egypt and 45 German inpatients with major depressive disorder (MDD, DSM-III) as well as in control samples of 50 Egyptian and German inpatients with acute medical diseases. Besides the "Beck Depression Inventory" (BDI) and the Hopelessness-Scale (H-Scale) the IPC-Scales were used, measuring internality, powerful others control and chance control in generalized control orientations. Results are: (1) Depressive inpatients are more depressive, more hopeless, more external, and less internal than patients with medical diseases; (2) While the Egyptian patients reach in general a markedly higher level in depression (BDI) than the patients in the German samples, a similar difference in the H-Scale was only observed for the depressive samples; (3) The Egyptian patients show distinctly higher scores in powerful others and chance control; (4) Discriminant analysis shows, that about 60% can be classified to the correct disease- and nationality-group by using the IPC-Scores; (5) There are some cultural specifica in the correlative patterns of the studied variables. It is concluded, that the results confirm on a general level the transcultural validity of cognitive approaches to depression. But it is noted as well, that cultural specificia in the structure of the cognitive orientations underlying depression require some differentiations of the constructs of such approaches.